Overview

Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)

Status:
Completed
Trial end date:
2020-07-30
Target enrollment:
Participant gender:
Summary
The proposed, three phase project will refine and test a first-ever care approach in SSA that combines LAI with a behavioral program specifically intended to promote medication adherence in chronic psychotic disorders (CPDs). In addition to the novel focus, innovative elements include: 1.) a manualized curriculum that targets specific barriers and facilitators to medication adherence in Tanzanians with CPD, 2.) targeting known, high-risk individuals with CPD (those who miss ≥20% of prescribed antipsychotic medication, and 3.) using existing injection clinic health workers to deliver the adherence promotion program. Strengths include the highly generalizable methods and use of LAIs that are available in low-resource settings.
Phase:
Phase 3
Details
Lead Sponsor:
Case Western Reserve University
Collaborators:
National Institute of Mental Health (NIMH)
National Institutes of Health (NIH)
Treatments:
Haloperidol
Haloperidol decanoate